BIMINI Biotech
BIMINI Biotech is a preclinical stage drug development company based in Leiden, The Netherlands, focused on creating innovative, first-in-class therapeutics for hematological cancers. Their proprietary technology targets the Wiskott-Aldrich Syndrome Protein (WASp), an actin nucleation-related protein exclusively expressed in hematopoietic cells, which has shown a potent anti-cancer effect. The company has a portfolio of small molecule WASp modulators, including a proprietary agonist, BM-011, which is in the pre-clinical stage and demonstrates potent activity in various lymphomas. They have recently secured a EUR 3 million seed investment round, led by Torrey Pines Investment, to advance the preclinical development of their WASp modulators and validate their safety and efficacy. BIMINI Biotech also leverages computer-aided drug design and AI-based systems for drug discovery.
BIMINI Biotech
BIMINI Biotech is a preclinical stage drug development company based in Leiden, The Netherlands, focused on creating innovative, first-in-class therapeutics for hematological cancers. Their proprietary technology targets the Wiskott-Aldrich Syndrome Protein (WASp), an actin nucleation-related protein exclusively expressed in hematopoietic cells, which has shown a potent anti-cancer effect. The company has a portfolio of small molecule WASp modulators, including a proprietary agonist, BM-011, which is in the pre-clinical stage and demonstrates potent activity in various lymphomas. They have recently secured a EUR 3 million seed investment round, led by Torrey Pines Investment, to advance the preclinical development of their WASp modulators and validate their safety and efficacy. BIMINI Biotech also leverages computer-aided drug design and AI-based systems for drug discovery.